She is co-founder of the Women's Cardiac Assessment and Risk Evaluation Program at the Mount Sinai Medical Center, serves on the editorial board of Focus on Healthy Aging and, as of July 2008, is a member of the American Heart Association's Boards of Directors (East Coast region).[3]
Mennell JS, Cesarman GM, Jacovina AT, Mclaughlin M, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia.N Engl J Med 1991; 340: 994-1004.
Mclaughlin M, Fuster V.Three mechanisms for coronary artery disease progression; insights into future management.Mount Sinai Journal of Medicine 1995; 62(4): 265-274.
Mclaughlin M, Phillips RA, Patel TN, Siu AL, David O, Buckley S, Mara T, Goldman ME. Prevalence and treatment patterns of diastolic filling abnormalities in the elderly. Journal of Heart Failure 1997; 4(1): 110.
Gersony DR, Mclaughlin M, Sacks HS, Fuster V, Gersony WM. Effect of beta blocker therapy on clinical outcome in patients with Marfans syndrome: Meta-analysis of data from 802 patients. JACC 1999; 33(2): 243.
Lala A, McLaughlin MA. Do all ACE inhibitors provide the same outcomes benefits in high-risk cardiovascular patients? Curr Hypertens Rep. 2008Aug;10(4):286-92. PMID18625157
Choi BG, McLaughlin MA. Why men’s hearts break: cardiovascular effects of sex steroids. Endocrinol Metab Clin North Am. 2007 June;36(2):365-77. PMID17543724
Khan RA, Moskowitz DM, Marin ML, Hollier LH, Parsons R, Teodorescu V, McLaughlin MA, Safety and Efficacy of High Dose Adenosine–induced A Systole During Endovascular AAA Repair. J Endovasc Ther 2000; 7:292-296.
Hebert, PL, Sisk JE, Wang, J, Horowitz, CR, Chassin MR, McLaughlin, MA. Cost-effectiveness of nurse-led disease management for heart failure in a racially diverse urban community. Annals of Internal Medicine, Accepted for publication 8/13/08.